BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target

Benzinga · 3d ago
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $57 price target.